Retroscreen exhibiting its hVIVO platform for accelerated drug development at American Thoracic Society International Conference 2014

May 16, 2014 2:00 pm

16 – 21 May, San Diego, USA

Retroscreen Virology Group plc (“Retroscreen” or the “Company”), will be exhibiting at the American Thoracic Society International Conference (ATS 2014) taking place in the San Diego Convention Center, San Diego, USA, on 16 to 21 May 2014.

ATS 2014 is one of the most comprehensive thoracic conferences in the international calendar, and offers the latest information on clinical, basic and translational science in pulmonary, critical care and sleep medicine.

A senior team from Retroscreen will be available in booth 2919 throughout the conference to discuss its pioneering approach to early phase clinical research using its hVIVO platform of human challenge models. The Company has delivered tremendous benefits for its clients in the areas of influenza, HRV and RSV across more than 35 studies to date. Retroscreen is now further expanding its platform and service offering in other disease areas related to viral infections, including asthma and COPD.

Kym Denny, Retroscreen’s CEO who will be leading a combined business development and medical team from Retroscreen, commented: “Retroscreen is the market leader in human viral challenge studies and our goal is to establish hVIVO as a key step in the development of influenza, RSV and respiratory disease products.We would like to communicate to drug sponsors at ATS 2014, how hVIVO can help accelerate proof of concept for new drugs and better inform their subsequent development.”

Should you wish to make contact with Kym Denny and the rest of the team whilst attending ATS 2014, or after the event, please call +44 (0)7972 503656 or email businessdevelopment@retroscreen.com.

Full details of the conference can be found at http://conference.thoracic.org/2014/.

Leave a Reply

Your email address will not be published. Required fields are marked *


*

Get in touch

Give us a call, or drop us an email. We'd love to hear from you!

Get in touch now